dm+d

Unassigned

New Medicines

AviganCOVID-19 treatment

Information

Avigan
New molecular entity
Cellvera
Cellvera

Development and Regulatory status

Compassionate use
Phase II Clinical Trials
Phase III Clinical Trials

Category

An anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase of RNA viruses. It is effective against a wide range of influenza viruses and other RNA viruses, e.g. arenaviruses, bunyaviruses and filoviruses [1].
Coronaviruses are a family of viruses transmitted between animals and people that can lead to respiratory illness, including MERS and SARS. On January 7, 2020, a novel coronavirus (Covid-19) was identified as the cause of pneumonia cases in Wuhan, China. As a group, coronaviruses are common across the world. Covid-19 was declared a pandemic on 11 March 2020. As of 1 April, the WHO reports 823,626 cases and 40,598 deaths worldwide [3].
COVID-19 treatment
Oral

AviganInfluenza

Information

Avigan
New molecular entity
Cellvera
Cellvera

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Jul 20Dr Reddys acquires favipravir. This is the second deal by Dr Reddys for a COVID-19 treatment within 20 days following the non-exclusive agreement with Gilead Sciences for marketing remdesivir. Unclear at this stage whether there are plans to develop for influenza (currently available in Japan for this indication) [11-13].
Jan 20Licensed and launched in Japan. FUJIFILM Toyama Chemical overseas pipeline does not include favipiravir for any indication. Development for influenza treatment appears to have been discontinued outside Japan.

Category

An anti-viral inhibitor of viral RNA polymerase that functions to make copies of the viral RNA segments and to synthesize mRNAs that produce the proteins that will form new viruses [1].
Up to 15% of the population can develop influenza in any year. There is a 10-20% seroconversion rate with or without symptoms. In an average year, there are 50-200 GP consultations for influenza or flu-like illnesses per 100,000 population per week (patient .co.uk)
Influenza
Oral